EU Commission clears KKR acquisition of Pfizer Capsugel unit; Meda says no approach from Valeant
Under European Union merger regulations, the European Commission has cleared the proposed acquisition of Capsugel by fund manager Kohlberg Kravis Roberts (KKR). Capsugel is being divested to KKR by US drugs behemoth Pfizer (NYSE: PFE) in a deal worth $2.38 billion to the latter company (The Pharma Letter April 5).
Capsugel manufactures dosage delivery products, such as hard gelatine capsules used for pharmaceutical products. The Commission's investigation showed that no horizontal overlaps arise from the transaction, since neither KKR nor any company that it controls are active in the same field as Capsugel.
KKR link with Alliance Boots not a problem
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze